Loading...
Transplant Monitoring Demand And FDA Clearance Will Drive A Powerful Long Term Upswing
AN
AnalystHighTarget
Not Invested
Community Contributor
Published
14 Dec 25
Views
10
14 Dec
US$6.09
AnalystHighTarget's Fair Value
US$9.00
32.3% undervalued intrinsic discount1Y
80.7%7D
-5.0%1Y
80.7%7D
-5.0%You can edit this narrative until Dec 15 8:10 AM. Then, changes will post as Updates.
Author's Valuation
US$932.3% undervalued intrinsic discount
AnalystHighTarget Fair Value